MEDICAL LETTER

Review Article
Volume: 2
Issue: 1

Peripheral Neuropathy: Understanding Diabetic and Chemotherapy-Induced Neuropathies

Dr. Amit Sachdeva And Nasim Ahmed

[1]*Assistant Professor, Department of Community Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India. Email: dramitsachdeva2410@gmail.com*
[2]*Independent Research, Guwahati, Assam India. Email: nasim@iarcon.org*

Received: Apr. 13, 2025; Revised: May. 09, 2025; Accepted: May. 26, 2025; Published: June. 30, 2025

Under a Creative Commons license Doi: 10.47310/medlet.2025.v02i01.009

Abstract: Peripheral neuropathy, characterized by pain, numbness, and weakness in the extremities, is commonly seen in patients with diabetes and those undergoing chemotherapy. Diabetic peripheral neuropathy (DPN) is driven by metabolic and microvascular damage linked to hyperglycemia, inflammation, and oxidative stress, while chemotherapy-induced peripheral neuropathy (CIPN) results from direct neurotoxicity of chemotherapeutic agents. Both forms can severely impact quality of life, with limited treatment options primarily focused on symptom relief. Recent advancements in understanding the pathogenesis of DPN and CIPN have led to novel therapeutic strategies, including pharmacological agents, non-pharmacological interventions, and emerging approaches like gene therapy, regenerative medicine, and neuromodulation. Early diagnosis, personalized management, and preventive strategies are essential to improving outcomes for affected patients.

Keywords: peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, neuropathic pain, neuroprotection, emerging therapies.

INTRODUCTION

Peripheral neuropathy is a disorder of the peripheral nervous system, often manifesting as weakness, numbness, and pain, typically in the hands and feet. It results from damage to the peripheral nerves, which disrupts the transmission of signals between the central nervous system and the rest of the body. Peripheral neuropathy can be caused by a variety of factors, but two of the most common types are diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN). Both forms of neuropathy can be debilitating, significantly affecting the quality of life of those who suffer from them.[1-7]

With diabetes on the rise globally and cancer treatments becoming more advanced but more aggressive, understanding the mechanisms, symptoms, risk factors, and treatment options for these neuropathies is crucial. This article delves into the pathophysiology, diagnosis, and treatment of both diabetic and chemotherapy-induced neuropathy, with a focus on recent advancements in management and care.

Diabetic Peripheral Neuropathy (DPN) [5-9]

1. Overview of Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy is one of the most common complications of both type 1 and type 2 diabetes. It affects up to 50% of patients with long-standing diabetes, and its prevalence increases with the duration of the disease, poor glycemic control, and other risk factors such as obesity and hypertension. DPN primarily affects the feet and legs, although it can also affect the arms and hands.

2. Pathophysiology of Diabetic Peripheral Neuropathy

The pathogenesis of DPN is multifactorial, with several interconnected mechanisms contributing to nerve damage.

Hyperglycemia and Oxidative Stress

Chronic hyperglycemia, the hallmark of uncontrolled diabetes, leads to several biochemical changes that damage peripheral nerves. One key mechanism is the production of advanced

glycation end-products (AGEs), which impair nerve function and structure. Hyperglycemia also promotes the activation of the polyol pathway, where excess glucose is converted into sorbitol, leading to oxidative stress and the depletion of essential cofactors such as NADPH. This increased oxidative stress causes damage to the small blood vessels supplying the nerves, resulting in nerve ischemia and injury.

Inflammation and Microvascular Damage

Hyperglycemia induces a pro-inflammatory state, characterized by the release of inflammatory cytokines such as TNF-α and IL-6. These cytokines promote endothelial dysfunction and disrupt blood flow to peripheral nerves, exacerbating ischemic damage. Additionally, microvascular damage in diabetes impairs the delivery of oxygen and nutrients to nerves, contributing to the demyelination and degeneration of nerve fibers.

Mitochondrial Dysfunction

Mitochondrial dysfunction has also been implicated in the pathogenesis of DPN. Mitochondria are critical for energy production, and their impairment results in energy deficits that make nerves more susceptible to damage from oxidative stress. The accumulation of reactive oxygen species (ROS) further damages nerve cells and impairs their function.

3. Clinical Presentation of Diabetic Peripheral Neuropathy

DPN typically presents with a gradual onset of sensory symptoms in a "stocking-glove" distribution, meaning that the symptoms begin in the toes and feet before spreading upwards to the legs, and eventually to the hands and arms.

Sensory Symptoms

- **Numbness and Tingling**: Patients often report numbness, tingling, or a "pins-and-needles" sensation in the extremities, particularly the feet.
- **Burning Pain**: Neuropathic pain is a hallmark of DPN and is described as burning, stabbing, or shooting in nature. This pain is often worse at night and can interfere with sleep.
- **Allodynia and Hyperalgesia**: Patients may experience heightened sensitivity to touch (allodynia) or exaggerated pain responses to stimuli that are normally non-painful (hyperalgesia).

Motor and Autonomic Symptoms

- **Muscle Weakness**: Although less common than sensory symptoms, DPN can cause weakness in the muscles of the feet and legs, leading to difficulty with balance and gait.
- **Autonomic Dysfunction**: Diabetic autonomic neuropathy can affect various organs and systems, leading to symptoms such as gastroparesis, orthostatic hypotension, and erectile dysfunction.

4. Diagnosis of Diabetic Peripheral Neuropathy

The diagnosis of DPN is primarily clinical, based on a patient's history of diabetes and characteristic symptoms. However, several diagnostic tools can aid in the assessment and staging of DPN.

- **Neurological Examination**: A thorough physical examination includes testing for sensory deficits, diminished reflexes, and signs of muscle weakness.
- **Nerve Conduction Studies (NCS)**: NCS can assess the speed and strength of electrical signals in the peripheral nerves, helping to confirm the diagnosis of neuropathy and assess its severity.
- **Quantitative Sensory Testing (QST)**: QST measures the patient's ability to detect various stimuli, such as vibration, pressure, and temperature, providing a more detailed assessment of sensory nerve function.

5. Treatment of Diabetic Peripheral Neuropathy

Glycemic Control

The cornerstone of managing DPN is tight glycemic control, as sustained hyperglycemia exacerbates nerve damage. Studies have shown that maintaining blood glucose levels within a target range can delay the onset and progression of DPN, particularly in patients with type 1 diabetes.

Pharmacological Management of Neuropathic Pain

Neuropathic pain in DPN can be challenging to manage, and several classes of medications are used to provide symptom relief:

- **Anticonvulsants**: Gabapentin and pregabalin are first-line treatments for neuropathic pain. These drugs modulate calcium channels to reduce neuronal excitability and pain transmission.

- **Antidepressants**: Tricyclic antidepressants (e.g., amitriptyline) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine) are effective in managing neuropathic pain by enhancing the inhibitory pathways in the central nervous system.
- **Topical Agents**: Capsaicin cream and lidocaine patches can provide localized pain relief for patients with DPN.

Non-Pharmacological Therapies

Non-pharmacological approaches such as physical therapy, acupuncture, and transcutaneous electrical nerve stimulation (TENS) may provide additional relief for patients with DPN. Foot care is also critical in preventing ulcers and infections, particularly in patients with sensory loss.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) [1-4,10-14]

1. Overview of Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect of many chemotherapeutic agents. It is estimated that up to 70% of patients undergoing chemotherapy develop some degree of CIPN, which can persist long after treatment has ended. The severity of CIPN varies widely, ranging from mild tingling to severe pain and functional impairment. The risk of CIPN depends on several factors, including the type of chemotherapy, cumulative dose, and individual susceptibility.

2. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

The pathogenesis of CIPN is complex and involves direct damage to peripheral nerves by chemotherapeutic agents. Several mechanisms have been proposed, depending on the specific drug used.

Axonal Degeneration

Many chemotherapeutic agents, such as platinum-based drugs (e.g., cisplatin, oxaliplatin) and taxanes (e.g., paclitaxel), cause axonal degeneration in sensory and motor nerves. This axonal damage leads to impaired signal transmission, resulting in sensory loss and motor weakness.

Mitochondrial Dysfunction

Chemotherapeutic agents, particularly platinum-based drugs, can disrupt mitochondrial function in neurons, leading to the production of reactive oxygen species and energy deficits. Mitochondrial dysfunction contributes to axonal degeneration and neuronal apoptosis.

Disruption of Microtubules

Taxanes and vinca alkaloids (e.g., vincristine) interfere with microtubule dynamics, which are essential for axonal transport. This disruption impairs the movement of organelles and proteins along the axon, leading to axonal degeneration and neuropathy.

3. Clinical Presentation of Chemotherapy-Induced Peripheral Neuropathy

CIPN typically presents with a symmetrical "stocking-glove" distribution of symptoms, affecting the hands and feet.

Sensory Symptoms

- **Tingling and Numbness**: The most common symptoms of CIPN are tingling, numbness, and a "pins-and-needles" sensation in the extremities.
- **Burning Pain**: Some patients report burning, shooting, or electric shock-like pain, which can be debilitating and interfere with daily activities.
- **Loss of Sensation**: Loss of sensation, particularly to vibration and temperature, can increase the risk of burns and injuries.

Motor and Autonomic Symptoms

- **Muscle Weakness**: Although less common, CIPN can cause motor symptoms, including weakness, muscle cramps, and difficulty with coordination.
- **Autonomic Dysfunction**: In rare cases, CIPN can affect the autonomic nervous system, leading to symptoms such as orthostatic hypotension and constipation.

4. Diagnosis of Chemotherapy-Induced Peripheral Neuropathy

The diagnosis of CIPN is primarily clinical, based on a patient's history of chemotherapy and characteristic symptoms. However, nerve conduction studies and quantitative sensory testing can be used to assess the severity of the neuropathy.

- **Patient-Reported Outcome Measures**: Self-reported questionnaires, such as the CIPN20, can help quantify the severity of symptoms and the impact of CIPN on daily functioning.
- **Nerve Conduction Studies**: These can confirm the presence of sensory and motor nerve damage and help differentiate CIPN from other forms of neuropathy.

5. Treatment of Chemotherapy-Induced Peripheral Neuropathy

Unlike DPN, where glycemic control is a key management strategy, CIPN requires a different approach focused on symptom relief and prevention.

Pharmacological Management of Neuropathic Pain

Several pharmacological agents are used to manage the neuropathic pain associated with CIPN, including:

- **Anticonvulsants**: Gabapentin and pregabalin are commonly used for neuropathic pain relief in CIPN, though their efficacy in CIPN is less well-established compared to DPN.
- **Antidepressants**: Duloxetine has been shown to provide modest relief for CIPN pain in clinical trials.
- **Topical Agents**: Capsaicin and lidocaine patches can be used for localized pain relief, although their efficacy in CIPN is variable.

Non-Pharmacological Therapies

Non-pharmacological treatments for CIPN include physical therapy, acupuncture, and integrative approaches such as massage and yoga. These therapies can help alleviate pain and improve mobility and quality of life.

Prevention of CIPN

Preventing CIPN remains a major challenge in oncology. Several strategies have been investigated to reduce the risk of CIPN, including the use of neuroprotective agents such as:

- **Glutathione**: An antioxidant that may reduce oxidative damage in neurons, though its effectiveness in CIPN prevention is still under investigation.
- **Calcium and Magnesium Infusions**: Some studies suggest that calcium and magnesium infusions can reduce the severity of CIPN caused by platinum-based chemotherapy.
- **Dose Modifications**: Reducing the dose or switching to less neurotoxic chemotherapy regimens may be necessary in patients at high risk of CIPN.

Recent Trends and Future Directions in Neuropathy Management [3,4,11,12]

1. Novel Therapeutic Approaches

Recent advances in the understanding of peripheral neuropathy have led to the development of novel therapeutic agents and strategies, including:

- **Gene Therapy**: Gene therapy holds promise for targeting the molecular mechanisms underlying neuropathy. Preclinical studies have shown that gene therapy can reduce pain and protect against nerve damage in animal models.
- **Regenerative Medicine**: Stem cell-based therapies are being explored as potential treatments for peripheral neuropathy. Stem cells have the ability to regenerate damaged nerves and restore function, though clinical applications are still in their infancy.

2. Emerging Pain Management Strategies

Chronic neuropathic pain remains one of the most challenging aspects of managing peripheral neuropathy. Emerging treatments include:

- **Cannabinoids**: Cannabinoids, such as cannabidiol (CBD), have shown promise in managing neuropathic pain in some studies. These compounds modulate pain signaling pathways and reduce inflammation.

Neuromodulation: Transcutaneous electrical nerve stimulation (TENS) and spinal cord stimulation (SCS) are being investigated as non-invasive and minimally invasive methods of reducing neuropathic pain.

CONCLUSION

Peripheral neuropathy, whether caused by diabetes or chemotherapy, is a significant clinical problem that can lead to debilitating pain, sensory loss, and functional impairment. Diabetic peripheral neuropathy results from a complex interplay of metabolic and vascular factors, whereas chemotherapy-induced peripheral neuropathy arises from direct damage to nerves by chemotherapeutic agents. Although both conditions present challenges in terms of diagnosis and treatment, recent advances in pharmacological therapies, non-pharmacological approaches, and preventive strategies offer new hope for patients suffering from these conditions. Continued research into the underlying mechanisms of neuropathy, as well as the development of novel therapeutics such as gene therapy and regenerative medicine, may lead to more effective treatments and improved quality of life for patients affected by these common and disabling conditions.

REFERENCES

1. Mattar M, Umutoni F, Hassan MA, Wamburu MW, Turner R, Patton JS, Chen X, Lei W. Chemotherapy-induced peripheral neuropathy: A recent update on pathophysiology and treatment. Life. 2024;14(8):991.
2. Sempere-Bigorra M, Julián-Rochina I, Cauli O. Chemotherapy-induced neuropathy and diabetes: A scoping review. Curr Oncol. 2021 Aug 19;28(4):3124-3138.
3. Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019 May;160 Suppl 1(Suppl 1):S1-S10.
4. Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomed Pharmacother. 2022;147:112671.
5. Mayo Clinic. Diabetic neuropathy: Symptoms and causes [Internet]. Available from: https://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/symptoms-causes/syc-20371580.
6. Galiero R, Caturano A, Vetrano E, Beccia D, Brin C, Alfano M, Di Salvo J, Epifani R, Piacevole A, Tagliaferri G, Rocco M, Iadicicco I, Docimo G, Rinaldi L, Sardu C, Salvatore T, Marfella R, Sasso FC. Peripheral neuropathy in diabetes mellitus: Pathogenetic mechanisms and diagnostic options. Int J Mol Sci. 2023 Feb 10;24(4):3554.
7. Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, et al. Diabetic peripheral neuropathy: Pathogenetic mechanisms and treatment. Front Endocrinol. 2024;14:1265372.
8. Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes. 2015 Apr 15;6(3):432-44.
9. UpToDate. Pathogenesis of diabetic polyneuropathy [Internet]. Available from: https://www.uptodate.com/contents/pathogenesis-of-diabetic-polyneuropathy.
10. Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019 Mar 22;20(6):1451.
11. Lee KT, Bulls HW, Hoogland AI, James BW, Colon-Echevarria CB, Jim HSL. Chemotherapy-induced peripheral neuropathy (CIPN): A narrative review and proposed theoretical model. Cancers. 2024;16(14):2571.
12. Loprinzi CL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38:3325-3348.
13. Maihöfner C, Diel I, Tesch H, et al. Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer. 2021;29:4223-4238.
14. Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.